GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sio Gene Therapies Inc (OTCPK:SIOX) » Definitions » Earnings Yield (Joel Greenblatt) %

Sio Gene Therapies (Sio Gene Therapies) Earnings Yield (Joel Greenblatt) % : 212.77% (As of Dec. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Sio Gene Therapies Earnings Yield (Joel Greenblatt) %?

Sio Gene Therapies's Enterprise Value for the quarter that ended in Dec. 2022 was $-13.95 Mil. Sio Gene Therapies's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was $-29.41 Mil. Sio Gene Therapies's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2022 was 212.77%.

The historical rank and industry rank for Sio Gene Therapies's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

SIOX's Earnings Yield (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -14.77
* Ranked among companies with meaningful Earnings Yield (Joel Greenblatt) % only.

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Sio Gene Therapies's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2022 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Sio Gene Therapies Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Sio Gene Therapies's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sio Gene Therapies Earnings Yield (Joel Greenblatt) % Chart

Sio Gene Therapies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial -500.00 -67.57 -212.77 -50.25 625.00

Sio Gene Therapies Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -384.62 625.00 263.16 172.41 212.77

Competitive Comparison of Sio Gene Therapies's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Sio Gene Therapies's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sio Gene Therapies's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sio Gene Therapies's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Sio Gene Therapies's Earnings Yield (Joel Greenblatt) % falls into.



Sio Gene Therapies Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Sio Gene Therapiess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2022 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-71.601/-11.807602
=606.40 %

Sio Gene Therapies's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.41 Mil.



Sio Gene Therapies  (OTCPK:SIOX) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Sio Gene Therapies Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Sio Gene Therapies's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sio Gene Therapies (Sio Gene Therapies) Business Description

Industry
Traded in Other Exchanges
N/A
Address
130 West 42nd Street, 26th Floor, New York, NY, USA, 10036
Sio Gene Therapies Inc is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis.
Executives
Parag V Meswani officer: Chief Commercial Officer 130 WEST 42ND STREET, 26TH FLOOR, NEW YORK NY 10036
Pavan Cheruvu officer: Chief Executive Officer C/O AXOVANT SCIENCES, INC., 11 TIMES SQUARE, 33RD FLOOR, NEW YORK NY 10036
Atul Pande director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Kristiina Md Vuori director C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
David W. Nassif officer: Principal Financial Officer C/O STEADYMED THERAPEUTICS, INC., 2410 CAMINO RAMON, SAN RAMON CA 94583
Senthil Vel Sundaram director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Dexxon Holdings Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 30600000
Andrew Lo 10 percent owner C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Svf Investments (uk) Ltd 10 percent owner 69 GROSVENOR STREET, LONDON X0 W1K3JP
Patrick Machado 10 percent owner 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Qvt Associates Gp Llc 10 percent owner 1177 AVENUE OF THE AMERICAS, 9TH FLOOR, NEW YORK NY 10036
Viking Global Performance Llc 10 percent owner 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901